Evelo Biosciences Inc.

2.89-0.0600-2.03%Vol 214.82K1Y Perf -70.47%
Aug 11th, 2022 16:00 DELAYED
BID2.50 ASK3.23
Open2.95 Previous Close2.95
Pre-Market- After-Market2.89
 - -  - -%
Target Price
17.30 
Analyst Rating
Strong Buy 1.33
Potential %
498.62 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
13.00 
Earnings Rating
Strong Buy
Market Cap311.85M 
Earnings Date
11th Aug 2022
Alpha-0.02 Standard Deviation0.30
Beta1.65 

Today's Price Range

2.753.29

52W Range

1.4212.74

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
2.85%
1 Month
22.98%
3 Months
54.55%
6 Months
-25.90%
1 Year
-70.47%
3 Years
-52.47%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EVLO2.89-0.0600-2.03
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.58-0.563.45
Q04 2021-0.61-0.5411.48
Q03 2021-0.57-0.63-10.53
Q02 2021-0.54-0.59-9.26
Q01 2021-0.53-0.55-3.77
Q04 2020-0.48-0.62-29.17
Q03 2020-0.50-0.4510.00
Q02 2020-0.71-0.6311.27
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.565.08Positive
9/2022 QR-0.61-3.39Negative
12/2022 FY-2.016.51Positive
12/2023 FY-1.6225.00Positive
Next Report Date-
Estimated EPS Next Report-0.56
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume214.82K
Shares Outstanding107.91K
Shares Float76.52M
Trades Count3.43K
Dollar Volume648.96K
Avg. Volume158.52K
Avg. Weekly Volume94.34K
Avg. Monthly Volume92.80K
Avg. Quarterly Volume288.42K

Evelo Biosciences Inc. (NASDAQ: EVLO) stock closed at 2.89 per share at the end of the most recent trading day (a -2.03% change compared to the prior day closing price) with a volume of 214.82K shares and market capitalization of 311.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 98 people. Evelo Biosciences Inc. CEO is Balkrishan Gill.

The one-year performance of Evelo Biosciences Inc. stock is -70.47%, while year-to-date (YTD) performance is -52.39%. EVLO stock has a five-year performance of %. Its 52-week range is between 1.4188 and 12.74, which gives EVLO stock a 52-week price range ratio of 13.00%

Evelo Biosciences Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 10.96, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -116.90%, a ROC of -144.46% and a ROE of -348.67%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Evelo Biosciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.56 for the next earnings report. Evelo Biosciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Evelo Biosciences Inc. is Strong Buy (1.33), with a target price of $17.3, which is +498.62% compared to the current price. The earnings rating for Evelo Biosciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evelo Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evelo Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.94, ATR14 : 0.27, CCI20 : 137.24, Chaikin Money Flow : 0.17, MACD : 0.18, Money Flow Index : 80.94, ROC : 32.57, RSI : 54.88, STOCH (14,3) : 67.48, STOCH RSI : 0.64, UO : 56.66, Williams %R : -32.52), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evelo Biosciences Inc. in the last 12-months were: Ara Darzi (Buy at a value of $499 999), David R. Epstein (Buy at a value of $25 000), David R. Epstein (Option Excercise at a value of $0), Duncan McHale (Buy at a value of $49 999)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
5 (83.33 %)
5 (83.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.33

Evelo Biosciences Inc.

Evelo Biosciences Inc operates as a bio-technology company. It is an immuno-microbiome company, develops immunotherapies for the treatment of cancer, oncology, neuroinflammation, metabolism, autoimmune, and inflammatory diseases. The company develops therapies for the treatment of the gut-body network.

CEO: Balkrishan Gill

Telephone: +1 617 577-0300

Address: 620 Memorial Drive, Cambridge 02139, MA, US

Number of employees: 98

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

TipRanks News for EVLO

Mon, 14 Mar 2022 13:45 GMT Analysts Offer Insights on Healthcare Companies: Evelo Biosciences (EVLO) and ImmunoGen (IMGN)

- TipRanks. All rights reserved.

Tue, 01 Mar 2022 13:51 GMT Evelo Biosciences (EVLO) Receives a Buy from BMO Capital

- TipRanks. All rights reserved.

News

Stocktwits